• +1-646-491-9876
    • +91-20-67278686

    Search

    Influenza A Virus H5N1 Subtype Infections-Pipeline Review H2 2017

    Influenza A Virus H5N1 Subtype Infections-Pipeline Review H2 2017

    • Report Code ID: RW00011060442
    • Category Life Sciences
    • No. of Pages 151
    • Publication Month Sep-17
    • Publisher Name Global Markets Direct
    Influenza A Virus, H5N1 Subtype Infections-Pipeline Review, H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H5N1 Subtype Infections-Pipeline Review, H2 2017, provides an overview of the Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline landscape.

    H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. Symptoms include fever and cough, acute respiratory distress, shortness of breath/difficulty breathing, abdominal pain and diarrhea. Predisposing factors include work with poultry, touch an infected bird and eating raw or undercooked poultry meat. Treatment includes antiviral medications.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H5N1 Subtype Infections-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H5N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 11, 1, 31 and 7 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively.

    Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).
    -The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    -The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    -The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    -The pipeline guide reviews key companies involved in Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
    -The pipeline guide evaluates Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    -The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    -The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease)

    Reasons to buy

    -Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    -Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    -Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).
    -Classify potential new clients or partners in the target demographic.
    -Develop tactical initiatives by understanding the focus areas of leading companies.
    -Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    -Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    -Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Global Markets Direct Report Coverage
    Influenza A Virus, H5N1 Subtype Infections-Overview
    Influenza A Virus, H5N1 Subtype Infections-Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Influenza A Virus, H5N1 Subtype Infections-Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Influenza A Virus, H5N1 Subtype Infections-Companies Involved in Therapeutics Development
    Akshaya Bio Inc
    Altimmune Inc
    Antigen Express Inc
    Aphios Corp
    BiondVax Pharmaceuticals Ltd
    CEL-SCI Corp
    Cocrystal Pharma Inc
    Curevac AG
    Gemmus Pharma Inc
    GlaxoSmithKline Plc
    Hemispherx Biopharma Inc
    iBio Inc
    Inovio Pharmaceuticals Inc
    Johnson & Johnson
    Kineta Inc
    Lakewood-Amedex Inc
    Medicago Inc
    Medigen Vaccine Biologics Corp
    Microbiotix Inc
    NanoBio Corp
    Nanotherapeutics Inc
    NanoViricides Inc
    OPKO Health Inc
    PaxVax Inc
    PeptiDream Inc
    Shionogi & Co Ltd
    Takeda Pharmaceutical Company Ltd
    TechnoVax Inc
    Vaxart Inc
    Vaxine Pty Ltd
    Visterra Inc
    Influenza A Virus, H5N1 Subtype Infections-Drug Profiles
    A-06-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AE-AI vaccine-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Alferon LDO-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    APP-0205-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    APP-309-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AT-301-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    beraprost sodium-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CC-42344-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CEL-1000-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CHOS-05-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DPC-005-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gamma-Flu-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GP-1002-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GP-1681-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GREFLU/VIE-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HAI-05-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HB-36.6-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Influ-nRNA-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strain A/H5N1] (split virion) vaccine-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strain A/H5N1] (virus like particle) vaccine 2-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strain A/H5N1] vaccine-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strain A/H5N1] vaccine-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strain A/H5N1] vaccine-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strain A/H5N1] vaccine-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strain A/H5N1] vaccine-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strain A/H5N1] vaccine-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strain A/H5N1] vaccine-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strain A/H5N1] vaccine 2-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H1N1 + A/H5N1] vaccine-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H5N1 + A/H1N1] (trivalent) vaccine-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H5N1 + A/H1N1] vaccine-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H5N1 + A/H5N2 + A/H7N2 + A/H7N3 + A/H9N2] (virus like particle) vaccine-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    INO-3510-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KIN-1148-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Lalistat-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    M-001-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MBX-2329-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MBX-2546-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibodies to Inhibit Hemagglutinin for Avian Infection and Swine Flu Infection-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibodies to Inhibit Hemagglutinin for Influenza Infections-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Inhibit Neuraminidase for Influenza A Virus H1N1 and H5N1 Infections-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MV-4-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Nasovax-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NVINF-1-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NVINF-2-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PD-001-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Peptides for Influenza Infections-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pimodivir hydrochloride-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PNSIA-28-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PNSIA-49-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PXVX-0103-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    S-033188-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Influenza A Virus H1N1 and H5N1 Infections-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Activate Sirtuin for Influenza-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptides for Influenza, HSV and HIV Infections-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptides for Viral Infections-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TVX-003-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VGX-3400X-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VH-244-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VIS-410-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Influenza A Virus, H5N1 Subtype Infections-Dormant Projects
    Influenza A Virus, H5N1 Subtype Infections-Discontinued Products
    Influenza A Virus, H5N1 Subtype Infections-Product Development Milestones
    Featured News & Press Releases
    Apr 24, 2017: Shionogi Presents New Clinical and Non-clinical Data on S-033188, an Investigational Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 27th European Congress of Clinical Microbiology and Infectious Diseases
    Apr 17, 2017: Shionogi to Present New Data on S-033188, a Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 27th European Congress of Clinical Microbiology and Infectious Diseases
    Sep 01, 2016: Abzyme Awarded Highly Competitive National Institutes of Health Phase II SBIR Grant
    Jun 01, 2016: NanoBio To Present Data Demonstrating Benefit Of Its Intramuscular Nanoemulsion Pandemic Influenza Vaccine
    Mar 22, 2016: Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress
    Sep 30, 2015: BiondVax Initiates a Phase IIb Clinical Trial in Europe for its Universal Flu Vaccine for Pandemic Outbreak
    Jun 02, 2015: Visterra Announces Presentation of Data at International Influenza Meeting on the Efficacy of VIS410 for Treatment of a Deadly Strain of Avian Influenza
    Mar 23, 2015: Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress in Washington D.C.
    Oct 29, 2014: BiondVax Receives Approvals for Patent in Europe and Japan for its Universal Flu Vaccine
    Mar 24, 2014: Valneva Announces the First Ever Marketing Authorization for a Human Vaccine Produced in the EB66 Cell Line
    Feb 17, 2014: BiondVax will Present Clinical Results and the Company's Strategy for Pandemic Preparedness Ahead of Flu Outbreak at the World Health Organization's Key Influenza Meeting
    Feb 10, 2014: BiondVax Receives Patent Registration Approval for Multimeric Multiepitope Influenza Vaccines in Hong Kong as well as Allowance of Patent Registration in US for the Company’s Universal Flu Vaccine
    Jan 21, 2014: BiondVax’s universal flu vaccine matches all 6 potentially pandemic flu strains in the world today: H5N1, H5N8, H6N1, H7N 7 , H7N 9 and H10N8
    Oct 03, 2013: BiondVax is a member of the UNISEC consortium awarded a European Commission FP7 grant of 6 million EURO
    Sep 09, 2013: Visterra Presents Prophylactic and Therapeutic Efficacy Data of VIS410 Against Multiple Influenza Strains with Pandemic Potential
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables
    Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017 (Contd..1), H2 2017
    Products under Development by Companies, H2 2017 (Contd..2), H2 2017
    Products under Development by Universities/Institutes, H2 2017
    Number of Products by Stage and Target, H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by Akshaya Bio Inc, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by Altimmune Inc, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by Antigen Express Inc, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by Aphios Corp, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by BiondVax Pharmaceuticals Ltd, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by CEL-SCI Corp, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by Cocrystal Pharma Inc, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by Curevac AG, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by Gemmus Pharma Inc, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by GlaxoSmithKline Plc, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by Hemispherx Biopharma Inc, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by iBio Inc, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by Inovio Pharmaceuticals Inc, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by Johnson & Johnson, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by Kineta Inc, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by Lakewood-Amedex Inc, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by Medicago Inc, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by Medigen Vaccine Biologics Corp, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by Microbiotix Inc, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by NanoBio Corp, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by Nanotherapeutics Inc, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by NanoViricides Inc, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by OPKO Health Inc, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by PaxVax Inc, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by PeptiDream Inc, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by Shionogi & Co Ltd, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by TechnoVax Inc, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by Vaxart Inc, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by Vaxine Pty Ltd, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Pipeline by Visterra Inc, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Dormant Projects, H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Dormant Projects, H2 2017 (Contd..1), H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Dormant Projects, H2 2017 (Contd..2), H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Dormant Projects, H2 2017 (Contd..3), H2 2017
    Influenza A Virus, H5N1 Subtype Infections-Discontinued Products, H2 2017

    List of Figures
    Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Number of Products by Top 10 Targets, H2 2017
    Number of Products by Stage and Top 10 Targets, H2 2017
    Number of Products by Top 10 Mechanism of Actions, H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
    Number of Products by Top 10 Routes of Administration, H2 2017
    Number of Products by Stage and Top 10 Routes of Administration, H2 2017
    Number of Products by Top 10 Molecule Types, H2 2017
    Number of Products by Stage and Top 10 Molecule Types, H2 2017
    Akshaya Bio Inc
    Altimmune Inc
    Antigen Express Inc
    Aphios Corp
    BiondVax Pharmaceuticals Ltd
    CEL-SCI Corp
    Cocrystal Pharma Inc
    Curevac AG
    Gemmus Pharma Inc
    GlaxoSmithKline Plc
    Hemispherx Biopharma Inc
    iBio Inc
    Inovio Pharmaceuticals Inc
    Johnson & Johnson
    Kineta Inc
    Lakewood-Amedex Inc
    Medicago Inc
    Medigen Vaccine Biologics Corp
    Microbiotix Inc
    NanoBio Corp
    Nanotherapeutics Inc
    NanoViricides Inc
    OPKO Health Inc
    PaxVax Inc
    PeptiDream Inc
    Shionogi & Co Ltd
    Takeda Pharmaceutical Company Ltd
    TechnoVax Inc
    Vaxart Inc
    Vaxine Pty Ltd
    Visterra Inc

    Request for Sample

    Report Url http://www.reportsweb.com//influenza-a-virus-h5n1-subtype-infections-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//influenza-a-virus-h5n1-subtype-infections-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//influenza-a-virus-h5n1-subtype-infections-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments